The present disclosure relates to a novel crystalline form E of Tafamidis meglumine, process for preparation and use thereof. When compared with prior crystalline forms, the novel crystalline form of the present disclosure has the advantages of simple process and low hygroscopicity, which provides a new and better choice for the development of Tafamidis meglumine drug product and is of great significance.